Thermon Group Holdings Inc
Electrical Equipment
Thermon Group Holdings Inc (THR) Stock News
The latest THR headlines and market coverage — 8 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aether Holdings, Inc. - ATHR
Pomerantz LLP is investigating potential securities fraud at Aether Holdings (ATHR), following a July 2025 short report by BMF Reports alleging fake filings, insider enrichment, lock-up violations, and undisclosed dealings. The allegations included concerns about a subsidiary acquisition with minimal business fundamentals. Aether's stock fell 23.95% on the report's publication.
- GlobeNewswire Inc.·
VALLOUREC AND ULTRA CORPOTECH PVT LTD SIGN A MEMORANDUM OF UNDERSTANDING FOR THE DEPLOYMENT OF ITS VAM® THREADING CAPABILITIES IN INDIA
Vallourec has signed a Memorandum of Understanding with Ultra Corpotech Pvt Ltd to deploy its VAM® threading capabilities in India. The partnership aims to establish localized production of premium tubular solutions for Oilfield Services customers, with implementation planned for late 2026 and commissioning expected in early 2027. This reflects the broader shift of manufacturing activities from North America to the Eastern Hemisphere.
- GlobeNewswire Inc.·
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.
- GlobeNewswire Inc.·
DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026
DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.
- GlobeNewswire Inc.·
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.
- GlobeNewswire Inc.·
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.
- Benzinga·
REPORT ON FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026
TORONTO , May 28, 2026 /CNW/ - Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSXV: UFC ) ("Urbanfund" or the "Company"), confirmed today that the Company has filed its financial statements for the three months ended March 31, 2026 (the "Consolidated Financial Statements") and corresponding Management's Discussion and Analysis ("MD&A"). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange ("TSX-V") under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund's focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company's assets are located in Toronto, Brampton, Belleville, Kitchener and London, Ontario, Quebec City and Montreal, Quebec and Dartmouth, Nova Scotia. Operational Highlights Part of Urbanfund's strength is its ability to attract partners with proven track records with both residential and commercial development expertise. Urbanfund continues to build alliances with its strategic partners: 1040 Martin Grove Road, Toronto – During the three months ended March 31, 2026, two commercial units were sold for sales proceeds of $778,732 (March 31, 2025, two commercial units for $841,776). To date, the Company's capital contribution of $1,870,000 has been fully returned, and an additional profit distribution of $822,545 has been received to date, of which $154,000 was received subsequent to the quarter end. 270-330 Esna Park Drive, Markham - During the three months ended March 31, 2026, four commercial units were sold for sales proceeds of $901,952 (March 31, 2025 – four commercial units for $691,991). To date, the company has received $1,462,521 of distribution, of which $382,427 was received subsequent to the quarter end.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA)
Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from approximately $1.9 billion to $2.4 billion.